RenovoRx Inc. is a biopharmaceutical company. It developed a therapy platform targeting difficult-to-treat tumors. RenovoRx Inc. is headquartered in Silicon Valley, California.
| Revenue (Most Recent Fiscal Year) | $0.04M |
| Net Income (Most Recent Fiscal Year) | $-8.81M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.75 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -4232.50% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -119.58% |
| Return on Assets (Trailing 12 Months) | -88.01% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.07 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.07 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.36 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.08 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.40 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.40 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 36.57M |
| Free Float | 33.23M |
| Market Capitalization | $49.37M |
| Average Volume (Last 20 Days) | 0.19M |
| Beta (Past 60 Months) | 1.12 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.13% |
| Percentage Held By Institutions (Latest 13F Reports) | 3.10% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |